Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
442 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Myelodysplastic Syndrome - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Myelodysplastic Syndrome - Pipeline Review, H2 2014', provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myelodysplastic Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myelodysplastic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Myelodysplastic Syndrome Overview 11 Therapeutics Development 12 Pipeline Products for Myelodysplastic Syndrome - Overview 12 Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis 13 Myelodysplastic Syndrome - Therapeutics under Development by Companies 14 Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 20 Myelodysplastic Syndrome - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Myelodysplastic Syndrome - Products under Development by Companies 25 Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 29 Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 30 Bristol-Myers Squibb Company 30 Boehringer Ingelheim GmbH 31 F. Hoffmann-La Roche Ltd. 32 Kyowa Hakko Kirin Co., Ltd. 33 Amgen Inc. 34 Eli Lilly and Company 35 GlaxoSmithKline plc 36 MedImmune, LLC 37 Daiichi Sankyo Company, Limited 38 medac GmbH 39 Merck & Co., Inc. 40 Sumitomo Dainippon Pharma Co., Ltd. 41 Gamida Cell Ltd. 42 Bio-Path Holdings, Inc. 43 Millennium Pharmaceuticals, Inc. 44 Novartis AG 45 Eisai Co., Ltd. 46 Pfizer Inc. 47 Astex Pharmaceuticals, Inc. 48 Teva Pharmaceutical Industries Limited 49 Cyclacel Pharmaceuticals, Inc. 50 Celgene Corporation 51 Incyte Corporation 52 4SC AG 53 Celldex Therapeutics, Inc. 54 Lorus Therapeutics Inc. 55 MEI Pharma, Inc. 56 OXiGENE, Inc. 57 Telik, Inc. 58 Array BioPharma Inc. 59 JW Pharmaceutical Corporation 60 Threshold Pharmaceuticals, Inc. 61 Synta Pharmaceuticals Corp. 62 BioAlliance Pharma SA 63 Cellerant Therapeutics, Inc. 64 Fujifilm Corporation 65 Chroma Therapeutics Ltd. 66 Ambit Biosciences Corporation 67 Actinium Pharmaceuticals, Inc. 68 Acceleron Pharma, Inc. 69 BioMAS Ltd. 70 Apogenix GmbH 71 Celator Pharmaceuticals, Inc. 72 TetraLogic Pharmaceuticals 73 Constellation Pharmaceuticals, Inc. 74 Cornerstone Pharmaceuticals, Inc. 75 Onconova Therapeutics, Inc. 76 Syndax Pharmaceuticals, Inc. 77 Concert Pharmaceuticals, Inc. 78 Mirna Therapeutics, Inc. 79 Kiadis Pharma B.V. 80 KaloBios Pharmaceuticals, Inc. 81 Targa Therapeutics Corp. 82 Formula Pharmaceuticals, Inc. 83 AbbVie Inc. 84 Clevexel Pharma SAS 85 Mirati Therapeutics Inc. 86 Myelodysplastic Syndrome - Therapeutics Assessment 87 Assessment by Monotherapy Products 87 Assessment by Combination Products 88 Assessment by Target 89 Assessment by Mechanism of Action 94 Assessment by Route of Administration 98 Assessment by Molecule Type 100 Drug Profiles 103 StemEx - Drug Profile 103 darbepoetin alfa - Drug Profile 105 ganetespib - Drug Profile 107 eltrombopag olamine - Drug Profile 111 ezatiostat hydrochloride - Drug Profile 114 treosulfan - Drug Profile 116 lenalidomide - Drug Profile 118 vosaroxin - Drug Profile 121 galunisertib - Drug Profile 123 entinostat - Drug Profile 125 ixazomib citrate - Drug Profile 129 SGI-110 - Drug Profile 131 sotatercept - Drug Profile 134 mocetinostat - Drug Profile 136 panobinostat - Drug Profile 139 tosedostat - Drug Profile 145 CPI-613 - Drug Profile 147 indisulam - Drug Profile 149 ATIR - Drug Profile 151 dasatinib - Drug Profile 153 pracinostat - Drug Profile 156 omacetaxine mepesuccinate - Drug Profile 158 sapacitabine - Drug Profile 161 (cytarabine + daunorubicin hydrochloride) - Drug Profile 163 quizartinib - Drug Profile 165 luspatercept - Drug Profile 167 rigosertib sodium - Drug Profile 168 KB-004 - Drug Profile 172 vorinostat - Drug Profile 174 AS-101 - Drug Profile 178 temozolomide - Drug Profile 180 INCB-24360 - Drug Profile 182 birinapant - Drug Profile 184 Iomab-B - Drug Profile 186 vismodegib - Drug Profile 188 acadesine - Drug Profile 191 trametinib dimethyl sulfoxide - Drug Profile 193 binimetinib - Drug Profile 196 ruxolitinib phosphate - Drug Profile 200 SL-401 - Drug Profile 204 Cell Therapy for Myelodysplastic Syndrome and AML - Drug Profile 206 erismodegib - Drug Profile 207 ALT-803 - Drug Profile 209 birinapant - Drug Profile 211 BPX-501 - Drug Profile 213 WT-4869 - Drug Profile 214 PD-616 - Drug Profile 215 Minor Histocompatibility Antigen - Drug Profile 217 (decitabine + E-7727) - Drug Profile 218 INCB-047986 - Drug Profile 220 AG-120 - Drug Profile 221 volasertib - Drug Profile 223 pevonedistat hydrochloride - Drug Profile 225 CDX-1401 - Drug Profile 227 azacitidine - Drug Profile 229 4SC-202 - Drug Profile 232 OXi-4503 - Drug Profile 234 everolimus - Drug Profile 236 pexmetinib - Drug Profile 240 TH-302 - Drug Profile 241 APG-101 - Drug Profile 248 HuM-195/rGel - Drug Profile 250 exatecan mesylate - Drug Profile 251 BP-100-1.01 - Drug Profile 253 MRX-34 - Drug Profile 255 ilorasertib - Drug Profile 257 glasdegib - Drug Profile 259 pembrolizumab - Drug Profile 261 CWP-232291 - Drug Profile 263 LGH-447 - Drug Profile 265 AG-221 - Drug Profile 266 FPI-01 - Drug Profile 268 MEDI-4736 - Drug Profile 270 Cell Therapy for Oncology - Drug Profile 271 Cell Therapy for Cancer - Drug Profile 272 FF-10501 - Drug Profile 273 CPI-0610 - Drug Profile 274 HDM-201 - Drug Profile 275 KHK-2823 - Drug Profile 276 GM-K562 Cell Vaccine - Drug Profile 277 LOR-253 - Drug Profile 279 MRx-102 - Drug Profile 281 ELP-10 - Drug Profile 283 CTP-221 - Drug Profile 284 FF-10501 - Drug Profile 285 Vaccine for Cancer - Drug Profile 286 CVXL-0056 - Drug Profile 288 Cancer Stem Cell Antibody Program - Drug Profile 289 Small Molecules for Myelodysplastic Syndrome - Drug Profile 290 Monoclonal Antibodies to Target CD16 and CD33 for Oncology - Drug Profile 291 Myelodysplastic Syndrome - Recent Pipeline Updates 292 Myelodysplastic Syndrome - Dormant Projects 424 Myelodysplastic Syndrome - Discontinued Products 425 Myelodysplastic Syndrome - Product Development Milestones 426 Featured News & Press Releases 426 Appendix 435 Methodology 435 Coverage 435 Secondary Research 435 Primary Research 435 Expert Panel Validation 435 Contact Us 436 Disclaimer 436
List of Tables Number of Products under Development for Myelodysplastic Syndrome, H2 2014 18 Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H2 2014 19 Number of Products under Development by Companies, H2 2014 21 Number of Products under Development by Companies, H2 2014 (Contd..1) 22 Number of Products under Development by Companies, H2 2014 (Contd..2) 23 Number of Products under Development by Companies, H2 2014 (Contd..3) 24 Number of Products under Development by Companies, H2 2014 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H2 2014 27 Comparative Analysis by Late Stage Development, H2 2014 28 Comparative Analysis by Clinical Stage Development, H2 2014 29 Comparative Analysis by Early Stage Development, H2 2014 30 Products under Development by Companies, H2 2014 31 Products under Development by Companies, H2 2014 (Contd..1) 32 Products under Development by Companies, H2 2014 (Contd..2) 33 Products under Development by Companies, H2 2014 (Contd..3) 34 Products under Investigation by Universities/Institutes, H2 2014 35 Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2014 36 Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H2 2014 37 Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 38 Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 39 Myelodysplastic Syndrome - Pipeline by Amgen Inc., H2 2014 40 Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H2 2014 41 Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline plc, H2 2014 42 Myelodysplastic Syndrome - Pipeline by MedImmune, LLC, H2 2014 43 Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 44 Myelodysplastic Syndrome - Pipeline by medac GmbH, H2 2014 45 Myelodysplastic Syndrome - Pipeline by Merck & Co., Inc., H2 2014 46 Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd, H2 2014 47 Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd., H2 2014 48 Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings, Inc., H2 2014 49 Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 50 Myelodysplastic Syndrome - Pipeline by Novartis AG, H2 2014 51 Myelodysplastic Syndrome - Pipeline by Eisai Co., Ltd., H2 2014 52 Myelodysplastic Syndrome - Pipeline by Pfizer Inc., H2 2014 53 Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 54 Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 55 Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 56 Myelodysplastic Syndrome - Pipeline by Celgene Corporation, H2 2014 57 Myelodysplastic Syndrome - Pipeline by Incyte Corporation, H2 2014 58 Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2014 59 Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics, Inc., H2 2014 60 Myelodysplastic Syndrome - Pipeline by Lorus Therapeutics Inc., H2 2014 61 Myelodysplastic Syndrome - Pipeline by MEI Pharma, Inc., H2 2014 62 Myelodysplastic Syndrome - Pipeline by OXiGENE, Inc., H2 2014 63 Myelodysplastic Syndrome - Pipeline by Telik, Inc., H2 2014 64 Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc., H2 2014 65 Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corporation, H2 2014 66 Myelodysplastic Syndrome - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 67 Myelodysplastic Syndrome - Pipeline by Synta Pharmaceuticals Corp., H2 2014 68 Myelodysplastic Syndrome - Pipeline by BioAlliance Pharma SA, H2 2014 69 Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics, Inc., H2 2014 70 Myelodysplastic Syndrome - Pipeline by Fujifilm Corporation, H2 2014 71 Myelodysplastic Syndrome - Pipeline by Chroma Therapeutics Ltd., H2 2014 72 Myelodysplastic Syndrome - Pipeline by Ambit Biosciences Corporation, H2 2014 73 Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 74 Myelodysplastic Syndrome - Pipeline by Acceleron Pharma, Inc., H2 2014 75 Myelodysplastic Syndrome - Pipeline by BioMAS Ltd., H2 2014 76 Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H2 2014 77 Myelodysplastic Syndrome - Pipeline by Celator Pharmaceuticals, Inc., H2 2014 78 Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H2 2014 79 Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 80 Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 81 Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics, Inc., H2 2014 82 Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 83 Myelodysplastic Syndrome - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 84 Myelodysplastic Syndrome - Pipeline by Mirna Therapeutics, Inc., H2 2014 85 Myelodysplastic Syndrome - Pipeline by Kiadis Pharma B.V., H2 2014 86 Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2014 87 Myelodysplastic Syndrome - Pipeline by Targa Therapeutics Corp., H2 2014 88 Myelodysplastic Syndrome - Pipeline by Formula Pharmaceuticals, Inc., H2 2014 89 Myelodysplastic Syndrome - Pipeline by AbbVie Inc., H2 2014 90 Myelodysplastic Syndrome - Pipeline by Clevexel Pharma SAS, H2 2014 91 Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc., H2 2014 92 Assessment by Monotherapy Products, H2 2014 93 Assessment by Combination Products, H2 2014 94 Number of Products by Stage and Target, H2 2014 97 Number of Products by Stage and Mechanism of Action, H2 2014 102 Number of Products by Stage and Route of Administration, H2 2014 105 Number of Products by Stage and Molecule Type, H2 2014 108 Myelodysplastic Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 298 Myelodysplastic Syndrome - Dormant Projects, H2 2014 430 Myelodysplastic Syndrome - Discontinued Products, H2 2014 431
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
